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ABSTRACT
CHARACTERIZATION OF REGULATORY MECHANISMS FOR
ALTERNATIVE SPLICING IN ALPHA THYROID
HORMONE RECEPTOR mRNA
Chao Zhang, B.S
Marquette University, 2010

In eukaryotes, alternative splicing is an essential post transcriptional modification process
for functional gene expression and a major contributor to protein diversity. The
regulation of alternative splicing generally involves the engagements of RNA sequences
cis-acting elements) and corresponding protein factors (trans-acting factors). The cisacting RNA motifs can be categorized depending on positional and functional differences.
Trans-acting protein factors will then bind to RNA sequences and affect the
corresponding splicing activity. Recently, factors associated with 3’ polyadenylation have
also been identified to affect alternative splicing.
In mammals, the α-thyroid hormone receptor gene (TRα) produces transcripts for two
functionally antagonistic isoforms, TRα1 and TRα2 by alternative splicing of pre-mRNA.
TRα1 will activate the thyroid hormone responsive genes after the binding of thyroid
hormone while TRα2, a non-hormone binding variant, plays a functionally antagonistic
role. A third minor isoform, TRα3 has also been described which is similar to TRα2 but
lacks part of the terminal sequence. Regulation of TRα alternative splicing requires the
interaction of cis-trans elements and alternative polyadenylation. The goal of my project
is to study the regulatory mechanism of TRα alternative splicing.
In our system, ESX10 (exonic splicing enhancer on exon10) was previously identified as
a 200 nt splicing enhancer element located on the last exon of TRα gene. My study
further characterized the enhancing capability of exonic splicing enhancers (ESE) motifs
within ESX10. Three heptanucleotide ESE motifs in the 3’ half of ESX10 have been
identified. In vitro experiments indicate that substitution of eight nucleotides within three
heptamers decreases the enhancing capability of ESX10. After substitution of ESX10 and
its subfragments with Rev-erbβ sequence, cryptic splicing was detected and quantitated.
Previous experiments also indicate that replacing original TRα1 and TRα2 poly (A) site
with a strong SVL poly (A) signal would increase the corresponding mRNA expression.
My results show that introduction of downstream poly (A) signal increases splicing
fidelity. When upstream 5’ss of TRα2 is disabled, the strong poly (A) signal enhances the
usage of weak splicing cites and promote cryptic splicing.
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Chapter I. Introduction
A. Background
Alternative splicing in α-thyroid hormone (T3) receptor gene
In higher eukaryotes, the expression of genes requires accurate and complete
transcription to produce functional pre-mRNAs. This primary transcripts is typically
modified by alternative splicing, a process in which spliced exons are connected after
intron removal [1, 2]. Most variations produced by alternative splicing are from splicing
at different splicing sites within mRNAs from a single gene, which normally leads to
expression of different protein isoforms. Since its discovery about 30 years ago,
alternative splicing has been addressed as an essential part of post transcriptional
modification and a major contributor to protein diversity from the genome [3, 4]. It has
been estimated that 95–100% of human genes with more than one exon undergo
alternative processing, which may account for the existence of far fewer protein coding
genes than originally predicted [5, 6, 7, 8]. Mistakes in alternative splicing are associated
with autoimmune disease, neurodegenerative disorders and various cancers [7, 8].

In mammals, the α-thyroid hormone (T3) receptor gene (TRα, also known as NR1A1)
produces transcripts for two functional antagonistic protein factors, TRα1 and TRα2
through alternative splicing of TRα pre-mRNA [9,10,11,12]. The mature mRNAs for
these two isoforms are identical except their 3' exons: TRα1 contains the complete
sequence for the first 9 exons while the production of TRα2 requires specific splicing
within exon 9 (at TRα2 specific 5' splice site) to exon 10 transcriptions (Figure 1). TRα1
mRNA encodes the authentic thyroid hormone receptor that activates the downstream
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thyroid hormone (T3) responsive genes after binding T3. In contrast, translation of TRα2
produce a non-hormone binding variant that competes for the same DNA binding domain
(T3 Response Elements) and will not involve in the following activation (Figure 1)
[11,12]. TRα3, a further spliced isoform of TRα, has also been identified in rat from TRα
alternative splicing. In TRα3, the proximal 39 amino acids sequence from exon10 of
TRα2 has been deleted. Functionally, TRα3 is similar to TRα2 in that TRα3 receptor
doesn’t bind to thyroid hormone and won’t activate downstream genes [13, 14].

In addition to the TRα1 and TRα2 mRNAs, mRNA for another nuclear receptor protein,
Rev-erbα is also transcribed from overlapping region but in the opposite direction [15,
16]. Rev-erbα has been confirmed to play an important role in circadian regulation by
controlling the transcription of BMAL1, one critical component of the molecular
apparatus that regulates circadian rhythms [17, 18]. Rev-erbα was originally identified as
an ‘orphan receptor’, which is a protein receptor that doesn’t have a known ligand.
However, recent studies demonstrated that heme reversibly binds to Rev-erbα in its
canonical ligand binding domain and regulate its interaction with other regulatory
proteins [17, 18]. Since TRα and Rev-erbα share a 263 nt exon-exon overlap at their 3’
ends and their respective transcripts may interact with each other, the relationship
between the sequence of these two physiological important genes has been studied by our
laboratory.

3
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TRβ and Rev-erbβ are two other nuclear receptor genes that are closely related to
TRα and Rev-erbα. In Homo sapiens, TRα and Rev-erbα are located on chromosome 17
while TRβ and Rev-erbβ genes are present on chromosome 3. Unlike TRα and Rev-erbα,
TRβ and Rev-erbβ don’t share overlap sequence and are separated by approximately 150
kb. Both TRα and TRβ encode for thyroid hormone receptors and mediate transcriptional
activity in conjunction with numerous coactivators and corepressors [20, 21, 22]. Our
study of TRα alternative splicing will provide insight for general alternative splicing
mechanism and the possible regulatory rate of the antisense overlap. It may also
contribute to understanding of the regulation of Rev-erbα.

The identification and functional analysis of cis-acting elements in TRα alternative
splicing
In eukaryotes, the regulation of alternative splicing requires the participation of RNA
sequence (cis-acting elements) and various protein factors (trans-acting factors), which
promote or inhibit the assembly of the functional spliceosome. To achieve successful
function of sequence motifs, different kinds of RNA-protein and protein-protein
interactions are anticipated. [23, 24, 25]. According to their positional and functional
difference, cis-acting RNA motifs can be categorized as: exonic splicing enhancer (ESE),
exonic splicing silencer (ESS), intronic splicing enhancer (ISE) and intronic splicing
silencer (ISS) [26, 27]. Trans-acting protein factor will then bind to these RNA sequences
and affect the corresponding splicing activity. Typically, serine-arginine family protein
factors (SR proteins) will bind to exonic splicing enhancers and positively affect the
splicing efficiency. Many heterogeneous nuclear ribonucleoproteins (hnRNPs) are known
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bind to ISS and ESS motifs and inhibit corresponding splicing activity. However, hnRNP
F and hnRNP H could contribute to splicing enhancement after binding to certain intronic
splicing enhancers [28, 29, 30]. Studies in our laboratory have been focused on the
mechanism for regulating alternative splicing of TRα. The role of cis acting elements and
polyadenylation on alternative splicing have been investigated in our system (Figure 2).

Production of functional TRα2 mRNA requires cis-acting elements and corresponding
tran-acting factors [31]. Previously, Dr. Michelle Hastings from our laboratory identified
the specific enhancer SEα2, an 80 nt segment downstream of TRα2 5' splicing site [32].
SEα2 is a highly conserved sequence motif located in exon 9, which is also the final
intron of TRα2. Substitution of the purine residues sequence inhibits the efficient splicing
of TRα2 in vitro. Studies from a series of truncated constructs indicate that deletion of
SEα2 induces a sharp decrease of normal TRα2 splicing in vivo [32]. The enhancing
capability of SEα2 was also examined using heterologous pre-mRNAs. SEα2 segment
was added to exon 4 in a truncated drosophila Dsx pre-mRNA [33, 34]. This change
increased Dsx splicing efficiency more than threefold comparing to the negative control.
SEα2's interaction with trans-acting factors was identified by in vitro competition
experiments. If SEα2 binds to protein factors necessary for TRα2 splicing, an excess of
SEα2 will inhibit TRα2 splicing competitively [32]. In competition experiments, different
concentrations of wild-type and mutant competitor RNAs were incubated with TRα2 pre-
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Figure 2. Regulatory mechanisms for TRα alternative splicing.
Alternative of TRα involves different regulatory mechanisms. The interaction of cis acting elements and trans acting factors is one major category of regulation. The cis acting motifs RNA can be categorized into: exonic
splicing enhancer (ESE), exonic splicing silencer (ESS), intronic splicing enhancer (ISE) and intronic splicing
silencer (ISS). Splicing silencer elements are shown in red, splicing enhancer elements in green. Both ISS and
ESS are hypothetical, while three different kinds of enhancing elements have been characterized. Selected
examples of protein known to regulate splicing and polyadenylation are also included: U1 snRNP, U2AF65/35,
SR protein, hnRNP proteins. Currently, we have identified SEα2, TR-ISE3 and ESX10 as cis acting elements in
our system. Interaction between SEα2 and SR protein factors has been identified[32]. Question mark indicate
hypothetical regulation elements shown for illustrative purposes.
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mRNA in HeLa nuclear extract for a fixed time period and corresponding TRα2 premRNA splicing efficiency was then evaluated. In contrast to mutant or non-specific RNA
competitors, SEα2 derived competitors efficiently inhibit normal TRα2 splicing in vitro.
Several tran-acting protein factors including SF2/ASF and hnRNPH were identified by
protein–RNA crosslinking with radio-labeled SEα2 RNAs [32]. These experiments
strongly suggested SEα2 and several associated protein factors are essential for
production of TRα2 mRNA. Alternative splicing is often affected by specific sequence
elements near the suboptimal 5’ or 3’ss [35]. TR-ISE3 (Thyroid Hormone Receptorintronic splicing enhancer-3’), a different type of cis-acting element was identified and
studied by Ms. Valerie Salato in our lab [36, 37]. Multi-method studies with truncated
constructs indicates that TR-ISE3 is a 90 nt sequence segment located upstream of
3’splice site of TRα2 (Figure 2). In vitro splicing studies suggest that the whole length of
TR-ISE3 is also essential for normal TRα2 production. Interestingly, SEα2 and TR-ISE3
seem to have an additive effect on enhancing TRα2 splicing [36, 37], which suggests that
they function independently. Such interaction between different cis-acting elements
might be critical for alternative splicing.

Another element important for splicing of TRα2 is ESX10 (exonic splicing enhancers on
exon10), originally identified by Ms Salato. Because exon10 is the terminal exon for
TRα2 and contains the overlapping region of two nuclear receptor proteins, the existence
of cis-acting elements might contribute to the regulatory mechanism for transcription of
both genes. Initially, a series of overlapping deletions were used to study the necessity of
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Figure 3 Schematic structure of ESX10 and its subfragment
A.

In order to further characterize ESX10, ESX10 segment (GR fragment) was
subdivided equally and named G100 and R100 according to their nearby
restriction sites. R100 was divided into 6 consecutive overlapping fragments and
named R42αA- R42αF starting from the 3’ end. Bioinformatics work predict that
three heptamer motifs of R100 might be short ESE targets.

B.

A truncated drosophila Dsx in vitro system was used to study the enhancing
capability of specific sequence segments. Without its original enhancer, the premRNA spliced poorly. G100, R100 and other interesting sequences were inserted
to the 3’ end separately to test enhancing ability. A-F indicate six 42 nt fragments
of R100, described above.
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ESX10 and successfully narrowed the size of enhancing fragment to 200 nt [36, 37]. It is
located downstream of TRα2 3’ss and named the GR fragment according to the
surrounding restriction sites (BsrGI and EcoRI). The enhancing capability of ESX10 has
been tested both in vitro and in vivo. Since Rev-erbβ sequence is 63% identical to the
Rev-erbα sequence but shows little enhancing capability in in vitro splicing test, it is used
in its antisense orientation as a negative control for the study of ESX10. Introduction of
ESX10 fragment into Dsx system induced a significant increase of Dsx exon splicing
compared to corresponding Rev-erbβ sequence. To characterize better the function of
ESX10 in vivo, new constructs have been made with the original ESX10 substituted by
corresponding Rev-erbβ sequence. Following transfections of HEK293 cells, total RNA
was assayed by realtime PCR. Results indicate that TRα2’s splicing was inhibited in the
absence of normal ESX10. To further characterize ESX10, the GR fragment was
subdivided equally into two fragments, named G100 and R100 according to their
adjacent restriction sites. When both G100 and R100 were inserted into Dsx for in vitro
splicing test, the R100 showed better enhancing capability [36, 37].

To better

characterize enhancing segments, R100 was divided into 6 consecutive overlapping
fragments and named R42αA-R42αF starting from the 3’ end [36, 37]. Each fragment is
42 nt long and overlapping 28nt with neighboring fragments and the enhancing capability
of each piece was tested with Dsx in vitro system (Figure 3B). All six fragments
promoted the splicing activity of Dsx pre-mRNA and their enhancing level were similar,
which also indicate the existence of multiple enhancing elements within R100. In order
to further characterize critical enhancing motifs, a series of R70 sequence were generated
with all possible combination of R42αF (R42βF) and 28nt R42αD’ (R42βD’) and their
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enhancing capabilities were evaluated in vitro by Dsx system. The fragments with TRα
sequence antisense to Rev-erbα displayed higher activity compared to the antisense Reverbβ (R70αFαD’ > R70αFβD ’> R70βFαD’ >> R70βFβD’) [36, 37]. This ordering
reflects the fractional representation of TRα sequence in each construct. The results from
this series of experiments suggested that the authentic TRα sequence is important for the
enhancing capability of ESX10 subfragments and we are interested in further studying
the enhancing elements within R100.

Alternative polyadenylation of TRα
In addition to splicing, alternative processing of TRα pre-mRNA also involves alternative
sites for polyadenylation [39, 40]. Polyadenylation is an important post-transcriptional
process for eukaryotic mRNAs and is involved in many processes including facilitating
translation, protecting mRNA from degradation in cytoplasm and exporting the mRNA
from the nucleus for translation.

The process of polyadenylation introduces many

adenylate residues to the 3’ end of the transcript. In animals, a typical signal associated
with polyadenylation is the hexanucleotide sequence AAUAAA located approximately
10-25 nt upstream of the polyadenylation site [40, 41, 42]. Each of the two TRα mRNAs
has a unique poly (A) site. Previous work by two students, Ms.Angela Schnell and Ms
Elizabeth Mackiel, contribute greatly to further analysis of the effect of polyadenylation
on TRα alternative splicing (Figure 2). The simian virus 40 (SV40) late mRNA share a
strong poly(A) site (SVL) and its sequence is used to represent the effect of strong
polyadenylation.
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A series of constructs have been made with SVL poly (A) site introduced to either TRα1
or TRα2 poly(A) site as a 175 nt, BamHI fragment. RNase protection assays (RPAs) and
realtime PCR were used to study TRα1 and TRα2 expression level. These studies showed
that SVL poly (A) signal substituted in TRα1 exon will aggressively compete with
normal TRα2 splicing and result in almost exclusive production of TRα1. When the
downstream TRα2 poly(A) site was replaced with the strong SV40 signal, the balance
between TRα1 and TRα2 mRNA expression was also altered, resulting in increasing
amounts of TRα2 splicing [S. Munroe and A. Schnell unpublished]. Unlike the exclusive
TRα1 production result from TRα1 poly (A) substitution, the downstream SV40 signal
will enhance TRα2 splicing but will not compete out TRα1 mRNA splicing. It appears
that both upstream and downstream poly (A) sites are critical for maintaining TRα1/
TRα2 ratio. Introduction of a stronger TRα2 5’ splice site with a single nucleotide
substitution (+5C/G) counteracts the effect of strong poly (A) signal of TRα1 and restore
the normal balance. Therefore, the strength of splice and polyadenylation sites also
affects the balance between splicing and polyadenylation. Since both cis-acting splicing
regulatory elements and polyadenylation are important for TRα alternative splicing it is
important to study the interactions between polyadenylation and ESX10 and investigate
their effects on the balance between TRα1 and TRα2. Using TRα system as model, we
hope to explore the underlying regulatory mechanism of alternative processing and
increase our understanding of the complexity of gene expression.

B. Specific aims
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As stated in the above introduction, the major goal of my study is to further identify and
investigate cis-acting elements in alternative splicing of α-thyroid hormone (T3)
receptor gene. Since polyadenylation also affects this process, the effect of strong
poly(A) signal on TRα alternative splicing has also been studied. The specific aims of
my study are:

1. To characterize three ESE motifs within R100 region of ESX10 and further study
the functional roles of ESX10 subfragments. These studies on ESE motifs are
carried out by substituting ESE motifs in exon 10 with corresponding homologous
sequence copied from the antisense strand of the Rev-erbβ gene sequence. The
enhancing effects of the chimeric fragments are tested by in vitro studies with Dsx
system. In vitro competition experiments are also used to characterize the functional
role of ESE motifs in TRα2 alternative splicing. To further study the requirements
for ESX10 activity, substitution of either half of ESX10 (GR) has been examined in
transfection experiments using a truncated TRα minigene plasmid.

2. To investigate the effect of polyadenylation sites in regulating TRα alternative
splicing. Previous work indicates that inactivation of ESX10 blocks the normal
TRα2 splicing. This effect of substituting a strong poly(A) site at 3’ end of TRα2
will be studied with respect to the activation of cryptic splicing within G100 and
R100 segments. Interestingly, the same strong poly(A) site enhances TRα2 splicing
fidelity by simultaneously reducing TRα3 expression, a shorter variant of TRα2
with a 3’ss within G100

13

Chapter II. Characterization of Bioinformatically Defined ESE Motifs
within ESX10 Enhancer
A. Introduction
In the Introduction we described the identification of ESX10 and the analysis of its
enhancing capability through in vitro splicing. In order to analyze comprehensively the
presence of typical ESE motifs within ESX10, we used bioinformatics approaches to
study its sequence and provide insights for further studies. Through bioinformatics
sequence analysis with Rescue-ESE program [43], three possible ESE motifs were
identified within the R100 fragment of ESX10. To further analyze their functional roles,
a series of in vitro experiments are used to study these ESE motifs. In this section I
describe the results from the bioinformatics studies, following in vitro splicing and
competition experiments to characterize the role of these ESE motifs in ESX10's
enhancing effect.

B. Further study of possible ESE motifs within R70 fragment
Since many ESE elements are 6-7 nucleotides segment that are sufficient for binding
specific SR proteins, several well-known programs including Rescue-ESE and FAS-ESS,
ESE-finder and Splicing rainbow are applied to analyze the ESX10 sequence and predict
possible ESE motifs. [43, 45, 46, 47]. By analyzing R100 sequence with Rescue-ESE
program [43], three heptamers have been identified and further analyzed. Although even
more clusters of Rescue hexamers are detected besides R100 in exon 10 (Figure 4), these
hexamers in R100 are intriguing since they overlap five of six previously tested 42nt

14

TRα2 3’ss

TRα3 3’ ss

BsrGI

R100

G/R
boundary

EcoRI

TRα2 stop

G100

Rev-erbα 3’ss
(antisense)

PflMI

Figure 4.Sequence information about ESE motifs on exon10.
ESX10 Sequence analysis with Rescue-ESE program. All predicted ESE hexamers within
ESX10 have been marked above the sequence. The box circled out are selected possible
ESE elements within R100 region. Each one of them is 7 nt long and comprised of two
overlapping ESE hexamers. BsrGI and EcoRI sites define the end of GR fragment. EcoRI
and the first PflMI site define the ends of the RM fragment.
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subfragments (R42αB-R42αF)[36]. Each heptamer contains two overlapping predicted
ESE hexamers and they are named Rescue1 (R1) Rescue 2(R2) and Rescue3 (R3)
depending on positional difference (Figure 4). After predicting these ESE elements'
position, various in vitro experiments are performed to directly test their effect on ESX10
enhancing capability.

1. Substitution of all three ESE motifs with Rev-erbβ sequence cause a sharp decrease of
the enhancing capability of ESX10 subfragment.
In order to determine whether these ESE segments are essential for ESX10’s activity, all
three motifs were substituted with the corresponding Rev-erbβ sequence. In the Rev-erbβ
sequence, R1 has 3 nucleotide substitution, R2 has 2 nt changed and R3 has 3 different
nucleotide compared to the authentic TRα sequence (Figure 5E). Overall, eight
nucleotide substitutions were introduced into R70αFαD’ (R123) and the modified
fragment was inserted into truncated Dsx exons to test its enhancing capability. After
adding chimeric fragment into Dsx system, the splicing activity (1.4%) dropped
dramatically compared to addition of the original R70αFαD’ sequence (60%). Thus, the
mutation of all three ESE motifs results a loss of 95% of the splicing activity (Fig 5A).
These results suggest that the authentic sequences of these ESE heptamers are essential
for maintaining the enhancing activity of ESX10 subfragments in vitro.
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2. Substitution of single or double ESE motifs with Rev-erbβ sequence reduces
enhancing capability of ESX10 subfragments in vitro.
After observing that the substitution of all three ESE motifs caused a large decrease in
R70 activity, we further studied the functional characteristics of each ESE element and
the interactive relationships between them. Similar to the strategy used to investigate the
effect of all three ESE heptamers, the substitution of each ESE motif was performed
independently with corresponding Rev-erbβ sequence and the mutated R70 sequences
were added to truncated Dsx exons to examine their effects (Figure 5B). The in vitro
splicing results showed that after introducing mutation to single ESE motif, the
enhancing activity of chimeric fragments decreased for every case. Among three ESE
motifs, the substitution of three nucleotides in R1 induces the most significant negative
effect on R70 enhancing capability, causing about 80% reduction on splicing activity
compared to the intact R70 fragment (Figure 5C; splicing percentage: 11% in R1
compared to 58% in αFαD’). Compared to the sharp drop in Dsx pre-mRNA splicing
after R1 substitution, the substitution of either R2 or R3 individually had slight effect on
splicing activity (Figure 5C: splicing percentage: 31% in R2 and 48% in R3 compared to
58% in αFαD’). From these results, we concluded that mutation of single ESE motifs
could also attribute to the enhancing effect of ESX10 subfragments and R1 motif might
be the critical for ESX10's overall enhancing function.

The successful splicing inhibition after substitution R1 ESE motif raised another
interesting question: is R1 the only contributor for ESX10's function or are the
contributions of other ESE elements (such as the R2 and R3 motifs) also required to
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achieve normal enhancing effect? To answer this question, we substituted every two out
of three ESE motifs and tested their effects with similar methods to investigate the
interaction between these elements (Figure 5B). The in vitro splicing results strongly
suggested that the ESE motifs would interact with each other and work cooperatively.
Mutation of R2 and R3 motifs alone only induced slight inhibitory effect on splicing
activity compared to R123 fragment (Figure 5D; splicing percentage: 32% in R23
compared to 65% in αFαD’ control; please see reference 36 for respective αFαD’ data).
And their mutations combined with R1 (R12 and R13) were much more effective in
inhibiting R70 enhancing activity (Figure 5D; splicing percentage: 8% in R12 and 7% in
R13 compared to 65% in αFαD’ control; please see reference 36 for respective αFαD’
data). Compared to αFαD’ control, he inhibitory effects from the double mutations with
R1 (R12 and R13) are slight lower than the substitution of all three motifs (R123) but
higher than substituting R1 alone (R1) [36]. Considering the close positional distance and
functional relationship between R2 and R3, it might be more reasonable to regard R2 and
R3 as another functional element (R2/R3) for ESX10. These results confirmed the critical
role for R1 heptamer on R70's enhancing capability and suggested that multiple
enhancing elements within R100 might cooperate with each other to promote TRα2
splicing.

3. Functional analysis of the ESE motifs by competition experiments.
Since many ESE motifs commonly bind members of the SR protein family, it was
possible that the trans-acting proteins within nuclear extract would interact with these
predicted ESE motifs. As a first step towards characterizing the involved protein factors,
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in vitro competition experiments were performed. If the ESE elements binds to the
protein factors present in nuclear extracts and these interactions are essential for the
enhancing capability, an excess of normal R70 RNA fragment with original ESE
sequence would competitively occupy necessary protein factors and inhibit the normal
splicing of TRα2 competitively. In contrast, an excess of chimerical fragment with
mutated ESE would not affect TRα2 splicing. In competition experiments, splicing
reaction containing radio-labeled truncated TRα2 were incubated with different
competitors RNAs (Figure 6A). The substrate pre-mRNA is transcribed from pα2 ∆BE
construct which contains partial TRα exon9 and exon10. Originally, the RNA substrate is
743 nt long and a final 430 nt product will be detected after intron removal from in vitro
splicing. The competitor RNA fragments include wildtype sequence (competitor WT: a
220 nt RNA fragment with wildtype ESX10 sequence), mutated sequence (competitor
Mut: a 170 nt RNA fragment with ESX10 that has 3 ESE motifs substituted with Reverbβ sequence) and corresponding Rev-erbβ sequence (competitor NS: a 220 nt RNA
fragment with Non-specific Rev-erbβ sequence) (Figure 6B). Besides, all competitors
have been applied to the pα2 ∆BE splicing with different concentrations. According to
the preliminary data, addition of 100nm competitor WT (original ESX10 sequence)
results in a 20% decrease on the splicing activity (Figure 6C). This result reflects specific
interaction between ESX10 and certain trans-acting factors present in the nuclear extract
because the mutated competitor Mut only have a slight inhibitory effect on splicing.
Comparatively, addition of the negative competitor NS (Rev-erb β sequence) didn’t
induce obvious competition effect either. These results suggest that the trans-acting
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The pα2 ∆BE pre-mRNA was incubated with 0, 50, or 100 nM of the labeled competitor
WT(wildtype: ESX10 sequence), competitor NS (Non-specific Rev-erb β sequence) and
competitor Mut(ESX10 sequence with mutated ESE motifs). All reactions were
incubated for 90 minutes and the samples were collected at 0 min, 45 min, 90 min.
The schematic structure of pα2 ∆BE pre-mRNA and competitor RNAs used in the
experiments
Percentage of Splicing for pα2 ∆BE in vitro splicing with different competitors.
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factors in Hela nuclear extracts are required for ESX10 activity and the previous
identified ESEs within this region might be critical in this cis-trans interaction.

C. Discussion
Regulation of alternative splicing involves the participation of various mechanisms and
one major contributor is the existence of different cis-acting elements and following cistrans interactions. In this chapter, my studies focused on the further characterization of
three ESE heptamers elements located within the 3’ half of ESX10. These ESE motifs
were original identified through detailed sequence analysis of ESX10 with bioinformatics
methods and their effects on the enhancing capability of ESX10’s subfragments are
investigated by in vitro splicing. Afterwards, competition experiments are applied to
further explore the possible cis-trans interaction within ESX10 region. My studies
indicate that the mutation of eight nucleotides within these ESEs dramatically reduced the
enhancer activity of ESX10 subfragments in vitro and also weakened the possible cistrans interaction.

The studies related to Exonic splicing enhancer motifs
In order to further study these ESE motifs within ESX10 region, the ESE sequences were
investigated by replacing single or all ESE motifs with corresponding Rev-erbβ sequence
and the enhancing capability of chimeric fragments are tested in vitro. Although my
experiments indicate that the mutation of ESE heptamers induced significant negative
effect on the enhancer activity of ESX10 subfragment, it is also possible that the effect is
not from the elimination of original enhancer element but from the introduction of new

23
silencer. FAS-ESS, a bioinformatics program that can predict the existences of ESS were
applied to test this hypothesis. After substituting three heptamers with Rev-erbβ sequence,
a reduction on number of possible ESE motifs and increase of potential ESS candidates is
predicted. In order to further study whether the inhibitory effect is from the disturbance
of original TRα2 sequence in heptamer motifs or from possible introduced ESS motifs,
we used other sequences combination besides the Rev-erbβ substitution to test the
enhancer activity of ESX10 subfragments. If other changes within these ESE regions
could reduce the splicing activity, the uniqueness of these ESEs could be confirmed.
Because R1 showed most significant effect among these three ESE motifs, we chose this
ESE heptamer and changed its sequence by random scrambling the order of the
nucleotides to disrupt the original ESE sequence (Generated with primers 774R and
775R). These scrambled motifs were introduced into Dsx system and tested similar as
other chimeric segments. Scrambled R1 sequence within the αR42F fragment showed
reduced enhancing effect than the original TRα sequence (for example, 35% splicing
αR42F compared to 23.2% splicing scrambled R1), although to a less extent than the 3nt
Rev-erbβ substitution(1.4%). The results from scrambled experiments suggest that the
authentic sequence of these ESE hepatmers might be critical for their enhancing effect
and disruption of the nucleotides constitution would negatively affect their function.
However, these in vitro splicing reactions showed high levels % input degradation(results
not shown) so further work is required to quantify the induced negative effect of these
substitutions.
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Chapter III. Functional Analysis of ESX10 and
its Subfragments (R100, G100)
A. Introduction
In Chapter II of this thesis, I described the positive effect of ESE elements located within
R100 region of ESX10. My goal in this chapter is to further characterize the importance
of ESX10 and its subfragments. Since both halves of ESX10 (G100 and R100) are highly
conserved, constructs with specific substitutions were created and used to further analyze
their effect on TRα2 splicing in vivo following transient transfection of HEK293 cells. In
this section, I describe the results from RNase Protection Assays(RPAs) and realtime
PCR experiments to characterize the functional role of ESX10 and its subfragmnets.

B. Study of ESX10, G100, R100 and the related cryptic splicing
1. Analyzing the effect of ESX10 and its subfragments by RNase Protection Assay
In order to investigate the functional importance of ESX10 and its subfragments on TRα2
alternative splicing, a series of TRα minigene plasmids with mutated ESX10 were
generated for expression in vivo. After equally dividing ESX10 into two segments
designated G100 and R100 according to their nearby restriction sites, plasmids that had
substitution of each half of ESX10 with Rev-erbβ sequence were created for further
studies: pErbAmβG100 (G100) and pErbAm-βR100 (R100). Another construct with the
whole ESX10 substituted by corresponding antisense Rev-erbβ sequence was generated
by Ms Schnell previously: pErbAm-βGR200 (GR200). After transfecting these three
constructs and other plasmids (the vector pRC/CMV as a negative control and
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Figure 7. Analyzing the effect of ESX10 or its subfragments by RNase Protection Assay
A.
B.

C.

The schematic structure of minigene plasmid we used in transfection. 293 HEK cells were tranfected and
total RNA were collected and assayed afterwards.
The probe used in the RPA overlaps 5’ss of TRα2, which indicate the expression of both TRα1 and TRα2
spliced mRNA. The arrows indicate the corresponding bands of either product. The tested samples are
different constructs with substituted ESX10 or its subfragments. The bottom panel is a high contrast
version of the same RPA assay. The abbreviations used in RPA and realtime PCR calculations are: CControl Vector, WT- wildtype control (pCMVerbAα). G100- Substituting G100 of ESX10 with Rev-erb β
sequence (pErbAm Revβ G100). R100- Substituting R100 of ESX10 with Rev-erb b sequence (pErbAm
Revβ G100). GR200 - Substituting ESX10 with Rev-erb b sequence (pErbAm Revβ G100).
The bar graph on the indicates the calculated TRα2 splicing percentage. The data used here were
averaged from at least three independent assays. RNAs are from two independent transfections assayed
in duplicate with different amount of input RNA.
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pErbA as a wildtype control) into HEK293 cells, total RNA was extracted and used as
substrate for RPA assays. RNAase Protection Assay was performed in order to compare
the effect of the minigene constructs on TRα2 splicing. The radio-labeled probe used in
RPA overlapped the TRα2 5’ splice site sequence in exon 9A (Figure 7A). Since TRα1
and TRα2 mRNA contain the shared exon9A sequence, the 5'ss probe will hybridize and
protect both products. In the assay, two different RNA concentrations (5 ug and 2.5 ug)
were used for each minigene and two independent experiments were performed. The
relative splicing levels of both TRα1 and TRα2 were calculated from two separate
experiments. The resulting data show that in the minigene without original ESX10
sequence (GR200), the splicing of TRα2 reduced greatly (2.8% splicing) compared to
wildtype control WT (20.5%) (Figure 7B and 7C). Substitution of either ESX10
subfragment (G100 or R100) also caused reduction of TRα2 compared to the wildtype
control (G100:9.0% and R100:11.5%), but their decreasing folds were lower than
substitution of the full ESX10 sequence (GR200) (Figure 7B and 7C). These results
suggest that ESX10 is functional important for TRα2 splicing in vivo and substitution of
ESX10 and its subfragments with Rev-erbβ sequence will also reduce normal TRα2
splicing.

2. Analyzing the effect of ESX10 or its subfragments by realtime PCR assay
Since the above RPAs would measure all splicing events at TRα2 5’ss, we use realtime
PCR to confirm the specific inhibition of TRα2 splicing. With primers specific for TRα1
and TRα2, realtime PCR assays were performed to further characterize the functional
importance of ESX10 and its subfragments (Figure 8A). From realtime PCR results, we
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Figure 8. Analyzing the effect of substitution of ESX10 or its subfragments
with Rev-erbβ by Realtime PCR methods
A.

B.

C.

The schematic structure of minigene plasmids we used for transfection. After collection of total RNA,
Reverse-Transcription PCR were used to generate cDNAs as templates for realtime PCR. Various primer
pairs were used to analyze the expression level of TRα1 and TRα2. In the figure, A and B stand for
primer set designed for different purposes. A- 936F, A1-937R, A2-1499b. B- 900F, B1-1467R, B2- 905R.
The sequence of primers are included in Appendix- E.
The calculated splicing percentage of TRα2 based on Realtime PCR data with primer set A/A1 and B/B1.
The data used were averaged from two independent Realtime reactions and each reaction had three
parallel assays, using primers pairs A/A1 for TRα1 and B/B1 for TRα2. % splicing is calculated from the
difference between CT values for TRα1(A/A1) and TRα2(B/B1) realtime PCR as described in Methods
(Chapter VI). These percentages assume negligible constrictions from alternatively spliced form
including TRa3 and cryptic splicing within βGR200 sequence.
Selected samples were assayed with 2% Agarose gel to test their matched size. The templates and
primer sets were indicated above the figure. The lower panel is a high contrast version of these bands.
CSS stands for products from cryptic splicing sites.
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confirmed our findings that substitution of both subfragments showed decreasing TRα2
splicing (Figure 8B). However, PCR analysis of minigene expression also revealed
differences. Using the primer set B/B1 specific for TRα2 detection, all the minigene
constructs expressed detectable levels of TRα2 mRNA as seen by electrophoretic analysis
(Figure 8C). However, with primer set B/B2, multiple spliced products were observed
and difference in expression patterns became apparent (Figure 8C). In the minigene with
wildtype, a shorted product was evident, which matches the size of TRα3, a previous
reported TRα isoform[13,14]. The subsequent sequencing of the additional product
confirmed the existence of TRα3 in our system and further studies about TRα3 will be
described in Chapter IV. With primer B/B2, G100 showed similar pattern as wildtype
control (WT), where TRα2 and a band with similar size to TRα3 were detected. However,
substitution of G100 with Rev-erbβ sequence eliminate key residues within the TRα3
3’ss (CAG/C

TTT/A). After analyzing the sequence results of the respective bands, it

is clear that the product with TRα3 size is not spliced from the authentic 3' TRα3 splice
site but from a cryptic splice site in the substituted Rev-erbβ G100 sequence, which is 2nt
downstream the position of authentic TRα3 splicing site (Table I). On the other hand,
R100 showed a similar banding pattern as GR200, where a different product from cryptic
splicing was predicted. The realtime PCR results indicate that both G100 and R100 have
enhancing effect and substitution of each subfrgament would induce decrease on TRα2
splicing. However, the electrophoretic analysis with primers B/B2 indicated that the
substitution of R100 induced greater inhibitory effect on TRα2 splicing (in Figure 8C,
G100 showed normal TRα2 band while R100 didn’t), which suggest that R100 is
functionally more important than G100.
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Table I. Sequence for 3’splice sites ofTRα2 and TRα3
positi
on

sequence

Consensus

N/A

YYYYYYYYNYAG/GNN

TRα2 3'ss

+1

CGTCTCGTAAAG/GAG

TRα3 3'ss

+117

CATGTTGTTCAG/GGU

TRα2 3'ss CSS(R100)

+194 TTCATTATTAAG/GUC

TRα3 3'ss CSS(G100)

+119

TGTTGTTTAAAG/AUC

In this table, R stands for purine nucleotides, N for random nucleotides.
3’ss and CSS respectively represents 3’ splicing site and cryptic splicing
sites.
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After isolating the additional products from R100, sequencing analysis confirmed the
existence of cryptic splicing product and its splicing site (Table I). The cryptic splicing
site located 197 nt downstream of TRα2 3’ss and 65 nt upstream of EcoRI site of GR
fragment, which belonged to the R100 region of substituted ESX10. We also identified
this cryptic splicing product in GR200 and more studies would be introduced in Chapter
IV.

Studying the expression level of cryptic splicing through realtime PCR
Based on the data from RPA assays and realtime assays, we concluded that substitution
of ESX10 with Rev-erbβ sequence (GR200) caused dramatically decreased TRα2
splicing and substitution of either ESX10 subfragment (G100, R100) reduced TRα2
splicing moderately compared to complete ESX10 substitution (Figure 9B). However, the
substitution of antisense Rev-erbβ sequence in ESX10 also introduced a cryptic
alternative 3’splice site. Therefore, the observation of cryptic splicing in G100, R100 and
GR200 raises the question whether the absence of ESX10 negatively affects the overall
splicing level or simply reduces TRα2 splicing accuracy? To answer the question, we
used realtime PCR methods with different primer sets to measure the expression level of
cryptic splicing.

In the experiments, primer set A/A2 was used to estimate the total expression of TRα
mRNAs. The percent splicing of TRα1, TRα2 and additional products are calculated
based on the realtime threshold value (CT) from different primer sets: A/A1 for TRα1 and
B/B1 for TRα2. B/B2 is designed to estimate the expression level of other splicing
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Figure 9 Comparing the splicing level of different components among minigenes
A. The schematic structure of minigene plasmids we used for transfection. Various primer
pairs were used to analyze the expression level of TRα1 and TRα2. A- 936F, A1-937R,
A2-1499b. B- 900F, B1-1467R, B2- 1495R, B2- 905R.(See Appendix- E for details)
B. Comparison of the calculated TRα2 splicing percentage between RNase Protection
Assays and Realtime PCR. TRα2 splicing in different minigene construct was compared
to the wildtype control(set as 100%). For RPA, The probe overlaps 5’ss of TRα2 was used
to indicate the expression of both TRα1 and TRα2 spliced mRNA. For Realtime PCR
assays, The calculated splicing percentage of TRα2 based on the data from primer set
A/A1 and B/B1. See Figure 7C and 8B for details.
C. Comparison of the expression of TRα1, TRα2 and downstream spliced products(include
cryptic splicing). The result was generated by calculating the corresponding percentage
with CT values from primer set A/A1(TRα1) ,B/B1(TRα2) and B/B2(For DS: downstream
splicing). CT values of A/A2 is set for the all the transcripts shared with exon8 and exon
9A. The %spliced represents the combined percentage of TRα1, TRα2 and downstream
(DS) product with different minigenes. Results of 2 or 3 respective experiments are
shown for each constructs.
D. Selected samples were assayed with 2% Agarose gel to test their matched size. The
templates and primer sets were indicated in the figure. The lower panel is a high
contrast version of these bands. Abbreviation for plasmids used in the Figure: C-control,
WT-wildtype, SVLα2-SVLα2, G100-βG100αR100, R100-αG100βR100, GR200-βGR200,
GR200+SVLα2-βGR200+SVLα2
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products downstream of TRα2 3’ss. Because this primer favors the smaller sized
products, it can be used to estimate the relative expression level of TRα3 and cryptic
splicing in comparing to selective constructs. Similar to conclusion from RPA and
realtime PCR assays, the results suggested that after substitution of ESX10 with Reverbβ sequence (GR200), the TRα2 splicing percentage reduced dramatically compared to
wildtype control (TRα2- GR200:2.6% compared to WT:20.4%) and TRα1 splicing
percentage increased correspondingly as well. (TRα1- GR200:96.3% compared to
WT:74.7%) (Figure 9C). Substitution of ESX10 subfragments (G100, R100) moderately
reduced TRα2 splicing (TRα2- G100:8% and R100:20.8%). With primer B/B2, splicing
products from different splice sites were indicated after PCR amplification (Figure 9D,
the panel with primer B/B2). The electrophoresis results indicated that in R100, GR200
and GR200+SVLα2 minigenes, only cryptic spliced products was produced. Because in
G100, normal spliced TRα2 is detected but in R100 we observe mainly cryptic splicing
products, we suggested that R100 is more important for TRα2 splicing than G100. This
statement also agrees with conclusions from previous in vitro experiments that R100
fragment showed more enhancing capability than G100 [36].

Although the substitution of ESX10 and its subfragments (R100) induced cryptic splicing,
the expression of cryptic splicing (DS- downstream splicing) in R100 and GR200 is
much lower compared to normal TRα2 splicing (DS splicing in R100: 0.1% and GR2000.1%; Compared to the TRα2 splicing in WT: 20.4%). These results suggest that ESX10
and R100 are functional critical for normal TRα2 splicing and the overall splicing level
was not reduced dramatically. Since the expression levels of introduced cryptic splicing
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products are much lower than TRα2, this conclusion would not be biased by the
appearance of cryptic splicing. Interestingly, the expression of downstream splicing after
ESX10 substitution was promoted greatly by strong downstream poly(A) signal (DSGR200:0.1%; GR200+SVLα2:18.2%). In next chapter, the effect of this strong
polyadenylation signal from the SV40 virus on splicing of TRα2 will be examined in
more details.

C. Discussion:
In this chapter, the functional role of ESX10 and its subfragments (G100 and R100) have
been studied through in vivo experiments. Constructs with substitution of ESX10 and
both subfragments (G100 and R100) have been created and RNase Protection Assays and
realtime PCR were used to evaluate the expression levels of normal spliced TRα2 and
related cryptic splicing.

Studies of ESX10 subfragments with RPA and realtime assays
In order to study the functional effect of ESX10 subfragments, both RNase Protection
Assay and realtime PCR assays were used to investigate TRα alternative splicing. In
RNase Protection Assay, the substitution of intact ESX10 with Rev-erbβ sequence
resulted a sharp decrease on TRα2 splicing (2.8%) compared to wildtype control
WT(20.5%). Substitution of either ESX10 subfragment (G100 and R100) with antisense
Rev-erbβ sequence causes reduction of TRα2 splicing (G100:9.0% and R100: 11.5%)
(Figure 7B and 7C). Although both G100 and R100 reduced TRα2 splicing, these
substitutions were substantially less effective than GR200. The realtime PCR data
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showed similar results. Compared to wildtype control WT(16.5%), GR200 resulted a
sharp decrease(0.2%) and the respective TRα2 splicing percentage for G100 is 6.0% and
R100 is 8.4%(Figure 8B). However, realtime PCR data in Figure 8B measured only
TRα2 splicing relative to TRα1 while the RPA results in Figure 7C measure all splicing
of the 5'ss in exon 9A. Therefore, both methods suggested that ESX10 sequence is
functionally important for TRα2 splicing and its subfragments(G100 and R100) also
indicate certain level of enhancing capability and the substitution of either half induced a
detectable drop on normal TRα2 splicing. The data also indicated that the G100
substitution caused more decrease on TRα2 splicing than R100 substitution, which
suggests that G100 might have more enhancing activity than R100 within the context of
the ErbAm minigene. However, this conclusion doesn’t agree with previous in vitro
results from our lab [36]. When R100 and G100 fragments tested in vitro, R100 enhanced
dsx pre-mRNA to almost same level as GR200 and G100 was much less efficient.
Another proof is that in R100, only cryptic splicing product can be detected with
electrophoresis and in G100 we observed mainly normal TRα2 product. Therefore, we
conclude that although substitution of G100 with Rev-erbβ sequence also causes
reduction of TRα2 splicing, R100 is more critical for TRα2 splicing and its substitution
will directly inhibit the normal TRα2 splicing. More work is required for studying the
expression level of TRα2 in G100 (pErbAm-βG100) to further investigate the effect of
G100 on TRα alternative splicing.

36
Validity of the R100 and G100 minigene constructs
After introducing the substitution of ESX10 subfragments (in G100 and R100 constructs),
we detect several nucleotide mutations outside of ESX10 as shown in Appendix A.
Compared to rat TRα sequence, one adenine has been mutated into guanine at 160 nt
downstream of EcoRI site (the 3’ end of ESX10) in G100 construct. In R100 construct,
one cytosine has been changed into thymine 210 nt downstream of EcoRI site and one
adenine has been changed to guanine in 271 nt downstream of EcoRI site. The
appearances of several point mutations within the newly generated constructs are
probably due to the error during recombinant PCR process. Although it is possible that
the introduced nucleotide changes might induce unpredictable results, we assume that
these few scattered mutations have trivial effect on TRα alternative splicing in these
minigenes.

Related studies concerning cryptic splicing
As the name describes, cryptic splicing involves splicing at sites not normally used.
Cryptic splice sites often resemble to normal splice sites but are not selected until a
mutation is introduced that alters usage of authentic splice site. In this Chapter, we
identify three cryptic splice sites downstream of TRα2 3' splice site. These include 3’
splice site for TRα3, a minor variant which was first describe more than 20 years ago [13]
and two sites introduced by Rev-erbβ substitution. The introduced cryptic splicing site in
G100 is very close to the TRα3 splicing site in original TRα sequence and therefore a
product have similar size to TRα3 was observed. In contrast, the R100 (pErbAm-βR100)
shares a similar cryptic splicing site in substituted R100 with GR200 (pErbAm-β200). As
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can be seen in Table I, these are all slightly poorer matches to the mammalian consensus
sequence. Interestingly, the two sites in the Rev-erbβ sequence both resemble the normal
TRα2 3'ss in that they have a AAG/G splice site sequence (Table I).

In our system, although the introduced cryptic splicing is close to the authentic TRα2
splicing site, the sequence for normal TRα2 3' splicing site has not been mutated. This
raises a challenging question related to the function of ESX10: does cryptic splicing
occur because of the missing of correct ESX10 sequence or does introduction of cryptic
splice sites compete with the normal splicing of TRα2? For cryptic splicing within in
GR200 and R100, the introduced cryptic splice site might not so strong as to compete
efficiently with the authentic TRα2 3’ss. Rather the absence of the enhancer activity of
ESX10 may change the splicing pathway for TRα2 5’ss. On the other hand, the cryptic
splice site within the G100 substitution is very close to the original TRα3 splicing
location. It is possible that (undefined) elements that direct splicing of TRα3 results in
selection another usable site near the original site. Although the importance of cryptic
splicing is trivial compared to the ESE studies, the selection between different sites
(strong or weak) might provide reasonable explanation for the interaction between cisacting elements and normal splicing factors.

The endogenous TRα2 in transfected HEK293 cells affect the realtime PCR results
One problem we encountered in the realtime PCR process is in transfected HEK cell or
cell transfected with vector as negative controls, we found a positive signal for TRα2
splicing. Although the expression level is much lower compared to the experimental ones,
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it would affect the measurement of minor splicing from analysis of realtime data. One
hypothesis is that endogenous TRα2 spliced in human cells would also be detected and
included in the CT values and low levels of TRα2 might represent cross contamination. In
order to solve this problem, we isolated the TRα2 PCR product obtained from
untransfected cells and compare the sequencing result from this sample with human and
rat sequence. Since the exon10 of TRα2 is highly conserved between these two species,
we used the nucleotides difference among exon 8 and exon 9 as major criteria for our
judgments and overall five nucleotides were accepted during the process. The sequence
results demonstrate the existence of endogenous TRα2 from human cell (Appendix-B).
Therefore, the CT values from realtime PCR correctly represent the expression level of
TRα2 and not adventitious contamination or some other artificial signal.
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Chapter IV. Effect of strong polyadenylation on TRα2 alternative splicing
A. Introduction
Polyadenylation is an important post-transcriptional process for eukaryotic mRNAs. This
chapter focuses on the contribution of polyadenylation to the regulation of TRα2 splicing.
In our system, the sequence of simian virus 40 late (SVL40) mRNA is used as a strong
polyadenylation signal, and the effect of this strong downstream poly(A) on TRα2 and
TRα3 expression was studied. We also investigated TRα2 splicing with a strong
downstream poly(A) signal when the ESX10 was substituted. Finally, the effect of strong
poly(A) signal on TRα2 splicing was also studied when authentic TRα2 5’ss was
disrupted.

B. Analysis of TRα3 splicing demonstrates that downstream SVL poly(A) signal
enhances the efficiency and fidelity of normal TRα2 splicing.
When using pCMVerbAα minigene as a wildtype control, TRα3, a different isoform of
TRα2 with a shorter size was detected by PCR (Figure 10B). Sequencing of the small
PCR product seen here and Table I also indicated that this product represents TRα3
3’spliced site, which is 117 nt downstream of the TRα2 3’ss (Figure 10A, Figure 4 and
Table I). Next, a known strong poly(A) site, late SV40 was inserted in place of
downstream TRα2 poly(A) site to test the effect of strong pA on TRα3 splicing.
Surprisingly, in the construct that has strong TRα2 poly(A) signal, the expression of
TRα3 was

reduced dramatically in comparison with the TRα2 mRNA (Fig 10B).

Realtime PCR results with primer specific for TRα2 splicing also showed that the strong
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Fig 10. Introduction of strong poly(A) site SVLα2 increase TRα2
splicing fidelity and eliminate TRα3 expression
A. Schematics structure of TRα2 and TRα3
B. Regular PCR results confirm an elimination of TRα3 expression and
increase on TRα2 expression. A/A1 and B/B1 were used.
C. Real-time data indicate that TRα2 splicing increases with strong downstream
polyadenylation. The results are from calculation of TRα2 percentage from a
combination of TRα1 and TRα2. (See Chapter V for more details)
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poly(A) signal enhances the expression level of regular TRα2 splicing compared to TRα1
splicing (Figure 10C). Thus it appears that inserting a strong poly (A) signal downstream
of TRα2 increases the splicing fidelity of correct TRα2. Expression level of TRα3
isoform would be inhibited and TRα2 splicing is enhanced.

C. Effect of the Strong Poly(A) Signal on Cryptic Splicing
1. The effect of downstream strong poly(A) signal on TRα2 splicing when normal TRα2
5’ss is disrupted
In an effort to determine wether the strong poly (A) for TRα2 can compete directly with
that for TRα1 in the absence of TRα2 splicing, transfection were carried with a minigene
construct that lack the TRα2 5’splice site (pErbAm ∆5'ss) paired with downstream strong
polyadenylation site of TRα2 (pErbAm ∆5'ss+SVLα2). It was expected that the major
products would be two RNAs differing only in their choice of poly(A) sites. In pErbAm
∆5'ss, six nucleotides were changed compared to the TRα2 5’ss consensus sequence
(Figure 11A) and previous results from our lab indicated that this mutation of TRα2 5’ss
(∆5'ss) completely blocks TRα2 splicing [44]. Conventional PCR results suggested that
disturbance of TRα2 5’ss also inhibited the expression level of TRα3(Figure 11B). TRα2
splicing is not enhanced by the strong TRα2 poly (A) signal when authentic 5’ss was
disturbed (pErbAm∆5'ss+SVLα2). However, cryptic splicing products were detected in
pErbAm∆5'ss and promoted by the SVL poly (A) signal (pErbAm∆5'ss+SVLα2) (Figure
11B). After sequencing the respective bands, two cryptic splice sites have been identified
located 53 nt and 142 nt downstream of normal TRα2 5’ss in exon 9 (Fig 11A). The
more distal site (CSS2) did not yield a clear sequence suggesting that the large
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A
CAG/ACCGCTCTGGCCTGCTGTGTGTGGACAAGATCGAGAAGAGTCAGGAGGCCTACCTGCTGGCGTT

3’ss
△5’ss: CC/CAC
TGAGCACTACGTCAACCACCGCAAACACAACATTCCGCACTTCTGGCCCAAGCTGCTGATGAAG/GTG
TRα2 5’ss(exon 9A)
AC GA
ACTGACCTCCGCATGATCGGGGCCTGCCACGCCAGCCGCTTCCTCCACAT/GAAAGTCGAGTGCCCCA

CSS1
CCGAACTCTTCCCCCCACTCTTCCTGGAGGTCTTTGAGGATCAGGAAGTCTAAAGCCTCAGGCGGCCA

TRα1 stop
GAGG/GTGTGC

CSS2

B
M

WT

∆5'ss ∆5'ss+SVLα2

TRα2
TRα3

Figure 11 Strong poly(A) site activates weak splice site near TRα2 5’ss
A. Sequence analysis of exon9 in TRα. Different splicing sites are marked: ss stands for
splicing site, CSS1 and CSS2 represents cryptic splicing sites 1 and 2. Sequence
substitutions in 5’ss of pErbAm △5’ss are shown above.
B. Conventional PCR amplification after reverse transcription are used to check TRα2
splicing. With constructs having mutated 5’ss for on exon 9, a decrease of TRα2 has been
detected. A strong poly (A) site will enhance the use of available weak splicing site and
increase the expression of cryptic spliced products. The primer set used to check cryptic
splicing is 936F/905R.
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PCR products may actually represent a mix of two (or more) products spliced a few
nucleotides apart. It appears that a strong downstream poly (A) signal enhances the usage
of weak splice site near the mutated TRα2 5’ss and increase cryptic splicing (Figure 11B).

2. The effect of downstream strong polyA signal on TRα2 splicing in the absence of
ESX10
As we discussed in the Chapter III, normal TRα2 splicing was reduced greatly after
ESX10 sequence substitution. Previous studies also showed that strong polyadenylation
site could enhance TRα2 splicing activity (Figure 12A, Lanes WT and SVLα2).
Therefore, a series of tests have been made to study whether a downstream strong poly
(A) signal will also induce positive effects on TRα2 splicing in the absence of ESX10. By
comparing the expression level of TRα1 and TRα2, we hope to investigate the
interactions between ESX10 and polyadenylation mechanism.

In order to study the effect of downstream strong poly (A) signal on TRα2 splicing in the
absence of ESX10, a strong poly (A) has been introduced into the construct that has
ESX10 substituted with corresponding Rev-erbβ sequence. Conventional PCR and
realtime assays were used to analyze the expression level of TRα2 and other spliced
product. The results from regular PCR indicated that normal TRα2 splicing was lost by
substitution of Rev-erbβ sequence in ESX10 and the additional strong SVL40 poly (A)
signal didn’t increase normal TRα2 splicing (Figure 12A). The usage of introduced weak
splicing sites near TRα2 3’ss were, however, enhanced after introducing downstream
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Figure 12 Downstream polyadenylation activates cryptic splicing at TRα2 3'ss
A.

Regular PCR bands indicate thatESX10 are critical for TRα2 correct splicing and
strong poly(A) signals will enhance general splicing level and increase correct
splicing with the existence of ESX10 enhancer.

B.

The schematic structure of different splicing sites of wt and GR200 from
sequence analysis and spliced product size.
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poly (A) site (Figure 12 B). The identity of the enhanced cryptic splicing products was
confirmed by sequencing.

D. Discussion:
In this chapter, we further studied the relationship between downstream polyadenylation
site strength and TRα2 alternative splicing. Previous results indicated that the
downstream poly(A) will promotes the nearby splicing and my results indicate that the
strong downstream poly (A) signal will not only enhance TRα2 splicing but increase the
fidelity of TRα2 splicing by reducing TRα3 splicing. One possibility is that ESX10
mediates the definition of exon 10, which may also explain why addition of the SVL site
eliminates TRα3 splicing. However, insertion of the strong poly (A) signal also activates
cryptic splicing at two sites near the 5’ss upstream in exon 9. In the absence of normal
TRα2 5’ss, these cryptic spliced products are promoted with TRα2 downstream
polyadenylation signal. With the antisense Rev-erbβ substitution for ESX10, the usage of
introduced weakly cryptic splicing sites is enhanced by the strong SVLα2 replacement at
TRα2 poly (A) site. Although the cryptic sites associated with ESX10 are only technical
problems, it confuses our analysis on the ability of the Rev-erbβ substitutions to block
normal TRα2 splicing.

Previous experiments showed that disruption of TRα2 5’ss by the mutation (∆5'ss) would
completely inhibit the TRα2 slicing. However, no cryptic splicing or TRα3 products
were observed in a previous study using northern blot analysis, presumably because that
technique is less sensitive than PCR [44]. In my experiments, the cryptic splicing was
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detected during the process of studying the effect of TRα2 downstream poly(A) on TRα2
splicing. With the primer A/B2, additional PCR products that are larger than those for
TRα2 and TRα3 were detected. After sequencing, we concluded that elimination of the
5'ss for TRα2 induces cryptic splicing at site 53 and 142 nucleotides downstream of the
mutant site (Table II). And these cryptic splicing were weak in the ∆5'ss without SVLα2
poly (A) site but their expression levels were greatly enhanced by TRα2 downstream
poly (A) (Figure 11C).

The sequence for cryptic splicing site 1(CSS1) was proved

consistent with reproducible experiments. However, the splicing site for CSS2 was not
located consistently and several splicing sites were identified by separate sequencing data
(CSS2 in Table II represent one confirmed CSS2 splicing sites). Therefore, we assume
that there might be multiple cryptic splicing sites available near the identified CSS2 site
and different products with similar size would be produced after disrupting correct TRα2
5’ss.

In this chapter, the presence of the cryptic sites associated with the strong SVL polyA site
were identified and investigated by various approaches. Although previous studies
indicate that the expression level of these cryptic splicing products is much lower than
normal TRα splicing(Figure 9C), the existence of these cryptic splicing complicate
analysis of possible interactions between the poly(A) site and the ESX10 splicing
enhancer. Further work to eliminate the expression of cryptic splicing in our system
would be helpful for characterization of the interaction between ESX10 and polyA and
their effect on TRα alternative splicing.
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Table II. Sequence of TRα2 5’ss and other cryptic splicing sites
position

sequence

Consensus

N/A

AAG/GURAGU

TRα2 5'ss

+1

AAG/GUGACU

TRα2 5'ss CSS1

+53

CAU/GAAAGU

TRα2 5'ss CSS2

+142

AGG/GUGUGC

In this table, R stands for purine nucleotides. 5’ss and CSS respectively
represent 5’ splicing site and cryptic splicing sites.
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V. Discussion and Conclusion
Advantage and limitation of mutation studies
The characterization of ESX10 and its subfragments was investigated by mutation studies.
These studies are normally carried out to further narrow down the key regulatory region
in a defined large fragment. If the authentic sequence contributes significantly to the
enhancing effect of ESX10, mutation of the target sequence would cause an increase or
decrease in the amount of splicing. However, if there is no effect after substitution, the
region might not be as important as hypothesized. In our system, TRα minigene provides
an good model to further study the regulatory elements, like enhancers within exon or
intron [32, 34, 36, 37].

The major limitation of this method is that mutations in vivo sometimes will activate
cryptic splicing sites either within mutated region or near mutated authentic splicing site.
In one study from Krainer and colleagues, the sequence difference between authentic 5'
splice sites and cryptic splice sites has been investigated [48]. Different statistical scoring
methods were used to compare the strength of authentic 5’ splice sites and cryptic
splicing sites. The authentic 5’ splice sites ranked highest among all the accepted
methods and the mutant sites ranked lowest. The cryptic splice sites received
intermediate score compared to the authentic 5’ss and mutant 5’ss. Interestingly, the
activated cryptic splicing sites were not necessarily the best scoring alternative sites near
the authentic 5’ splicing sites, which suggests that other factors could also contribute to
cryptic splicing sites selection. For example, relative usage of cryptic splicing sites near
normal 5’ss would be affected by increasing SR protein or hnRNP A/B in mutant
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substrates of Hbb(human β-globin gene) [49, 50]. In our system, the cryptic splicing
activated after disrupted TRα2 5’ss could be due to the loss of authentic splicing site.
And the cryptic splicing happened within substituted ESX10 or its subfrgaments (G100
and R100) might be due to the dysfunction of ESX10 and existence of other factors
involved in alternative splicing. Further efforts on identifying the trans-acting factors
would be necessary to characterize the mechanisms involved with ESX10 and its
subfragments.

The advantages and disadvantages of in vivo and in vitro methods
In this thesis, I applied both in vivo and in vitro methods to investigate the identification
and characterization of cis-acting elements for TRα2 splicing. The major advantages of
Dsx in vitro splicing system are its sensitivity and quick application. Since this splicing
system lacks its original enhancer and relies totally on the introduced enhancing segments,
even an enhancer with low level could be investigated and slight change on the enhancing
capability could also be easily detected. In R100, three ESE candidates have been
predicted by Rescue-ESE program and their activities were tested through in vitro
experiments (Figure 5). After testing, the R1 ESE motif seems to be the most efficient
one among these three motifs and we can conclude that one important factor that could
contribute significantly for the ESX10 activity and following TRα2 splicing. However, in
the following in vitro competition experiments, the fragment with substituted R1, R2 and
R3 did not compete against the pre-mRNA splicing as efficiently as authentic GR170
fragments (Figure 6C). This suggests that the mutated fragments don’t bind some factors
essential for TRα2 splicing. Combining the in vitro and in vivo results, we cannot
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determine whether the segments overlapping R1 R2 R3 are necessarily the only ones
required for TRα2 splicing. Further work would include narrowing the competitor
fragments(from current GR170 to R70) and detecting trans acting factors.

Although in vitro experiments are very sensitive for detecting possible enhancer elements,
there are also disadvantages: in the in vitro system, the effect of certain factors inside the
cell might be neglected and their absence or perturbation may affect the enhancing
capability in real situation and biased the accuracy of our conclusion. Therefore, in vitro
splicing test is useful approach for analyzing the activity of enhancers and in vivo studies
would be helpful to confirm the results convincingly. Thus we further characterize the
functional importance of ESX10 subfragments with a series of in vivo studies after
creating constructs with substitution of either G100 or R100. The results from RNase
Protection Assay and realtime PCR suggested that both ESX10 subfragments had
enhancing capability on TRα2 splicing and substitution of either G100 or R100 would
caused the decrease on TRα2 splicing (Figure 7 and 8). On the other hand, the
substitution of G100 reduced TRα2 splicing more effectively that the R100 substitution,
which suggests that factors associated with G100 may also contribute significantly to
TRα alternative splicing. However, previous in vitro experiments confirmed that R100
had more enhancing capability than G100, which against the conclusion we draw through
RPA and realtime assays.

The contradictions between the enhancing capability of ESX10 subfragments in in vitro
and in vivo experiments may be due to several reasons. First, when we test the activity of
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G100 and R100 through in vitro experiments, the enhancing capability cis-acting
elements and trans-acting factors on the boundary of the subfragments (upstream
sequence of G100, boundary between G100 and R100, downstream sequence of R100)
would be affected and their original function might be significant. Second, although the
dsx in vitro experiments are sensitive approach for detecting enhancers, minor difference
between in vitro and in vivo experiment (ie. the in vitro incubation environment and in
vivo cell growing) could induce unexpected effect on the final results. Therefore, further
efforts on identifying what proteins bind to ESX10 is necessary to better understand the
mechanism and solve the problem. Combining the results from both in vivo and in vitro,
we further characterize the functional role of ESX10 subfragments and increased our
understanding on the regulatory mechanism of ESX10.

Studies related to Polyadenylation and cis-acting elements
Generally, cis-acting elements normally work as the docking sites or targets for transacting factors and affect the activity of the nearby splice sites [51, 52, 53].
Polyadenylation has also been confirmed to affect splicing through protein-protein
interactions among polyadenylation factors and splicing factors, where downstream
polyadenylation positively affect the activity of proximal splice site [54]. Splicing and
polyadenylation factors also interact with RNA polymerase II and other interactions
before transcription and processing are also likely to occur. Therefore, the next goal was
to investigate the possible interactions between cis-acting elements and downstream poly
(A) signals.
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Recent studies also pointed to important interactions between chromatin structure and
alternative splicing. For example, studies of the fibroblast growth factor receptor2
(FGFR2) gene illustrate a possible relationship between histone modification and
alternative splicing may provide insight into our results [55]. In this study, distinctive
histone modifications were shown to correlate with the effects of cis-acting elements on
the splicing outcome in a series of human genes. The recruitment of the splicing
regulatory protein PTB that binds to RNA would be affected by a chromatin-binding
protein MRG15. Thus alternative spicing events may be regulated through this adapter
system. Given these results, it is quite possible that polyadenylation factors also directly
or indirectly interact with similar components of chromatin. If such interactions can be
confirmed, the bridge between cis-trans interaction mechanism and polyadenylation
mechanism could be established.

Conclusions and Summary
In this thesis, we explored the role of ESX10 and the downstream poly (A) on promoting
or facilitating TRα2 splicing. Three possible ESE motifs within ESX10 were identified
and their enhancing effects on TRα2 splicing were investigated in vitro. Following in
vivo approaches were applied to further characterize the functional importance of ESX10
subfragments. In the end, we studied the effect of strong downstream poly (A) on TRα2
splicing and other related splicing events (TRα3 and cryptic splicing). The results from
these experiments suggest that the existence of cross-exon interactions involve three
elements: the 3'ss, the ESEs (ESX10) and the pA site. This network of interactions may
be targeted or affected by antisense RNA produced through transcription of the opposite

53
strand (Rev-erbα) indirectly, by altering the modification of the chromatin. The roles of
TRα1 and Rev-erbα as two regulatory proteins important for developmental regulation,
differentiation and metabolic control suggest that expression of this locus may be
regulated in many different ways. TRα2 might function as an additional layer of
regulation that modulates expression of these genes. The physiological role of TRα2 is
also itself remarkably elusive. More than 20 years after its discovery the function of this
protein is unknown despite the fact it is highly conserved and its expression is
differentially regulated in different cells and tissues of eutherian mammals. This study
may help to expand our current knowledge on regulatory mechanism of TRα alternative
splicing and the possible interaction between TRα2 and other thyroid hormone receptor
proteins.
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VI. Materials and Methods
Plasmids
Constructs with ESX10 Subfragments Substitution
To further investigate the functional effect of subfragments of ESX10, substitution of
either halves of ESX10 was introduced into minigene constructs. The parent vector used
was 633(pErbAm delta 2+SVLα2), which has a 200nt truncation downstream of EcoRI
site on exon10. The mutated G100 (βG100αR100) and R100 (αG100βR100) insertion
fragments were created by recombinant PCR. For G100, primer 979F and 1493R were
used to create upstream βG100 fragment and 982R and 1492F were used for downstream
αR100 fragment. The recombinant βG100αR100 fragment was generated with 979F and
982R. For R100 construct, Primer 979F and 1491R were used to create upstream αG100
fragment and 982R and 1490F was used to generate downstream βR100 fragment.
Similarly, the recombinant αG100βR100 fragment was generated with 979F and 982R as
well. Both parent vector and the insertion fragments were digested with BsrGI and SbfI
restriction enzymes and ligated by T4 DNA Ligase after digestion. Since the insertion
introduced a 200 nt longer fragment into the parent vector, the mutations were confirmed
by Bsu36I restriction enzyme digestion and sequencing results. During the sequencing
process of the new constructs, several point mutations have been identified downstream
of ESX10 (Appendix C). Although we didn’t detect any obvious cis-acting elements near
the region where these mutated nucleotides were identified, these changes might
introduce unpredicted effect on the potential regulatory mechanisms near these regions.
Other used plasmid can be found in Appendix-D.
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Cell lines: HEK293 cells (also referred as Human Embryonic Kidney 293), is derived
from tissue culture of human embryonic kidney cells and stored in our lab.

Transfection and RNA isolation
The calcium phosphate mediated transfection was set up according to the standard
procedure of Sambrook et al (1989). HEK293 cells were plated as concentration of
2×10^6 per P100 plate 24 hours before transfection and 48 hours before RNA extraction.
After one day, 5 ug of plasmid DNA calcium phosphate were transfected into each plate.
The cells were rinsed 24 hours after transfection and fresh media was introduced. The
RNA extraction was performed with RNA extraction buffer and 2x PK buffer. DNaseI
and PK were used in the process to purify and concentrate the target RNAs. RNA
extraction from part of the transfection undergoes Trizol prep extraction (TRIzol
Isolation of RNA, DNA and Protein, Invitrogen).

RNase Protection Assay
To obtain the TRα1/TRα2 mRNA alternative splicing ratio, specific probes were
designed according to the corresponding sequence. The DNA used to produce the radiolabeled probes was generated by PCR with designed primers. Different probes were
generated according to different spliced product and cryptic splicing. Various
concentrations of RNA and probes were hybridized overnight. RNase Cocktail containing
RNases A and T1 and following Proteinase K treatment were used to stop the reaction.
The samples were extracted, ethanol precipitation, resuspended in FSB and load on a 5.5%
polyacrylamide-urea gel.

56
In vitro transcription and splicing
Most RNA substrates were generated with PCR templates. Different types of polymerase
(T7 or SP6) were used according to promoter specificity. After Mix and incubate at 37 ºC
for 60 minutes. DNase I was used to eliminate the residual DNA templates. After
overnight EtOH precipitation, RNA pellets will be resuspended in 20 ul FSB and load on
to polyacrylamide-urea gel to further isolate. Otherwise, equal volume of urea gel stop
buffer can be added after in vitro transcription reaction and the mixture will be loaded
onto a polyacrylamide gel. After treatment with elution buffer for 4 hours, phenol
extraction and following precipitation are used to purify the RNA. For in vitro splicing
reaction, nuclear extract was incubated with pre-mRNAs, and a certain portion of
reaction was taken out after a fixed time period and incubates with PK for 25min. After
precipitation, labeled RNA was resuspended in FSB and load to 5.5% gel.

Quantitation of assays
The dried gel after RPA and in vitro splicing were analyzed by scanning with Storm
phosphor-imager to collect counts of each detectable band. Because the amount of
unlabeled UTP and labeled hot UTP were preset before the reaction, the different number
Us in different product are used to measure the actual percentage of spliced mRNA
against unspliced product.

Quantitation of mRNA expression level from realtime PCR
After converting mRNA into complementary DNA with reverse transcriptase, we use
realtime PCR to investigate the expression level of mRNAs. Since DNA amount doubles
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after every cycle of PCR until it reaches the corresponding thresholds, the Ct values can
be used to calculate the percentage of each product(TRα1, TRα2 or cryptic splicing
product). . And the difference between TRα1 and TRα2 Ct values was used to measure
TRα1/ TRα2 ratio. The lower Ct value is, the higher the initial mRNA presents in the
reaction. And the specific calculation shows below:
In Figure 8B, we use primer set A/A1 for TRα1 and B/B1 for TRα2 detection
%TRα2 splicing = 100*TRα2/( TRα1+ TRα2) = R*100/(R+1)
[R= TRα1/ TRα2 = 2Ct(B/B1)− Ct(A/A1)]
In Figure 9B, we use primer set A/A1 for TRα1, B/B1 for TRα2, B/B2 for CSS and
A/A2 to detect the expression of all the transcripts with shared exon8 and exon 9A.
%( TRα1+ TRα2+CSS) = 100* (TRα1+ TRα2+CSS)/(all transcripts)
[TRα1/ (all transcripts) = 2Ct(A/A2)− Ct(A/A1)]
[TRα2/ (all transcripts) = 2Ct(A/A2)− Ct(B/B1)]
[CSS/ (all transcripts) = 2Ct(A/A2)− Ct(B/B2)]
In Figure 9C, the expression level of TRα1 and TRα2 were calculated.
%TRα1 = 100*TRα1/( TRα1+ TRα2+CSS)
%TRα2 = 100*TRα2/( TRα1+ TRα2+CSS)
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Appendix-C
Plasmid name
pHB∆6

Catalog #
9

pBS500
pRC/CMV
pCMVerbAα
pCMVB324/5'ss
pα2 ∆BD
pα2 ∆BE
pα2SE80∆BD
pErbA2 ∆BE
pErbA2 ∆BE SE60
pDSX100XK
pCMV324 α2 pA SVL

101
210
220
352
493
494
505
555
556
585
613

pErbAM∆5'ss SVLα2
pErbAm ∆RM

625
632

pErbAm SVLα2
pErbAm Revβ 200
pErbAm Revβ 200
SVLα2

633
635

pErbAm Revβ G100

647

pErbAm Revβ R100

648

636

Description and application
β globin sequcne; negative control for in vitro splicing and competition
tests
β globin sequcne; negative control for in vitro splicing and competition
tests
negative control for transfection and ESX10 study
wildtype construct for transfection and ESX10 study
disrupted 5'ss of TRa2 and for poly(A) study
TRa2 exon8-10; in vitro splicing and competition tests
TRa2 exon8-10; in vitro splicing and competition tests
TRa2 exon8-10 and SEa2 included; in vitro splicing and competition tests
∆BE fragment inserted; vector for constructs making
∆BE fragment inserted and SE60;in vitro splicing and competition tests
exon10 sequnece included; for in vitro transcription
substitued poly(A) downstream; for poly(A) study
disrupted 5'ss of TRa2 with substituted poly(A) downstream; for poly(A)
study
200nt downstream of EcoRI site of exon10 truncated; for poly(A) study
200nt downstream of EcoRI site of exon10 truncated + donwstream
poly(A) signal; for poly(A) study
ESX10 replaced by β sequemce; for ESX10 study
ESX10 replaced by β sequemce and introduced poly(A) downstream; for
ESX10 study
G100 replaced by β sequemce and introduced poly(A) downstream; for
ESX10 study
R100 replaced by β sequemce and introduced poly(A) downstream; for
ESX10 study

Vector

Application

Source

pSP6

in vitro splicing

SHM

pGem4
pCMV
pCMV
pCMV
pGem3
pGem3
pGem3
pGem3
pGem3
pDsx
pCMV

in vitro splicing
transfection, PCR
transfection, PCR
transfection, PCR
in vitro splicing
in vitro splicing
in vitro splicing
in vitro splicing
in vitro splicing
in vitro splicing
transfection, PCR

SHM
SHM
LV
SHM
SHM
SHM
SHM
VS
SHM
SHM
AS

pCMV
pCMV

transfection, PCR
transfection, PCR

SHM
SHM

pCMV
pCMV

transfection, PCR
transfection, PCR

AS
AS

pCMV

transfection, PCR

AS

pCMV

transfection, PCR

CZ

pCMV

transfection, PCR

CZ
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Appendix-D
Primers for in vitro studies
Number
701L

Description of plasmid construct
pDsx (upstream primer)

Direction
F

705L

Dsx/KX-R42αD

R

706L

Dsx/KX-R42αE

R

707L

Dsx/KX-R42αF

R

711L

Dsx/KX-R42βD

R

713L
723L
724L
725L
726L

Dsx/KX-R42βF
Dsx/KX-R70αFαD'
Dsx/KX-R70αFβD'
Dsx/KX-R70βFαD'
Dsx/KX-R70βFβD'

R
R
R
R
R

735L/R

Dsx/KX-R42αFRescue1
42aF(rescue1)

R
F

736L/R

Dsx/KX-R42αDRescue2,3
42aD(rescue2,3)

R
F

737L/R

Dsx/KX-R70αFαD'Rescue1,2,3

R

738L/R
720R

Dsx/KX-R42αE(RSCU1,2)

R

R70aFaD'
R70bFbD’

Sequence (5' to 3')
CGGCCAGTGAATTGTAATACG
CTAGA GCTCTTCGGG CTCTGGTGCT GAAGAACCGG CCCTCGGAGA CT
TACCGCGATCCAAGCTTATC
CTAGA GGTGCT GAAGAACCGG CCCTCGGAGA CTTCCCGCTT CACCAA
TACCGCGATCCAAGCTTATC
CTAGA GG CCCTCGGAGA CTTCCCGCTT CACCAAACTG CTGCTCAAGC
TACCGCGATCCAAGCTTATC
CTAGA GCACTAAGGA CCTTAATAAT GAAAAACCAT CCAAATGAGG CC
TACCGCGATCCAAGCTTATC
CTAGA AT CCAAATGAGG CCTCTATTTT TACAAAACTG CTTCTAAAGT
TACCGCGATCCAAGCTTATC
CTAGAGCTCTTCGGGCTCTGGTGCTG
CTAGA GCA CTA AGG ACC TTA ATA ATG AAA AAC CGG CCC TCG GAG ACT TCC CG
CTAGA GCT CTT CGG GCT CTG GTG CTG AAG AAC CAT CCA AAT GAG GCC TCT AT
CTAGA GCA CTA AGG ACC TTA ATA ATG
CTAGA GGCCCTCGGAGACTTCCCttTTtACCAAACTGCTGCTCAAGC
TACCGCGATCCAAGCTTATC
GCTTGAGCAGCAGTTTGGTaAAaaGGGAAGTCTCCGAGGGCC
CTAGA Gca Cta aGG GCT CTG GTG aTG Aaa AAC C GG CCC TCG GAG ACT
TACCGCGATCCAAGCTTATC
AGTCTCCGAGGGCC/GGTTtTTCAtCACCAGAGCCCttAGtGC
GCaCTaaGGGCTCTGGTGaTGAAaAACCGGCCCTCGGAGACT
CTAGA GCA CTA AGG ACC TTA ATA ATG AAA AAC C GG CCC TCG GAG ACT TCCCt
CTAGA GGTGaT GAAaAACCGG CCCTCGGAGA CTTCCCttTTtACCAA
TACCGCGATCCAAGCTTATC
GCAGTTTTGTAAAAATAGAGGCCT
GCT TGA GCA GCA GTT TGG TGA AGC GGG AAG TCT CCG AGG GCC /GGT TCT TCA GCA
CCA GAG CCC GAA GAG C
ACT TTA GAA GCA GTT TTG TAA AAA TAG AGG CCT CAT TTG GAT /GGT TTT TCA TTA TTA
AGG TCC TTA GTG C

68
759R
760R
761R
762R
763R
764R
765R

Rescue 1,2,3 rectified
Rescue1,3-rectified
R70 aFD(R3)
R70 aFD(R1)
R70 aFD(R2)
rescue 2,3
rescue 1,2

R
R
R
R
R
R
R

766R

R42xtD

R

767R

R42xtE

R

768R
769R
770R
771R

R42xtF
R70xtFxtD'
R70xtFaD'
R70aFxtD'

R
R
R
R

773R
774R
775R

R
R
R

780R

Dsx/KX-R42αD (R2)
Dsx/KX-R42αF (ScR1)
Dsx/KX-R42αF (ScR2)
FD'(R123) primer matched to
R100

781R
782R
783R
784R
785R
786F
787F
788F
789R

betaG70
alphaG70
betaG100
alphaG100
DsxKX
aG fragment
bG fragment
Rescue overlap
Rescue overlap

R
R
R
R
R
F
F
F
R

790R
791F

Rescue mutated
recombinant F(paired with 790R)

R
F

R

CTA GA GCAC TAA GGG CTC TGG TGA TGA AAA ACC GGC CCT CGG AGA CTT CCC t - 3'
CTAGA GCACTAA GGGCTC TGG TGC TGA AGA ACC GGC CCT CGG AGA CTT CCC t - 3'
CTA GAG CAC TAA GGG CTC TGG TGC TGA AGA AC
CTA GAG CTC TTC GGG CTC TGG TGC TGA AGA ACC GGC CCT CGG AGA CTT CCC T
CTAGA GCTCTTC GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TC
CTAGA GCaCTaa GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TC
CTAGA GCTCTTC GGGCTCT GGTGaTG AAaAACC GGCCCTC GGAGACT TCCCt
CTAGA GCc CTT CGtt CcC T ca TcC TGA AGA Aca Gt Cca aac Gat A Cc
TACCGCGATCCAAGCTTATC
CTAGA ca TcC TGA AGA Aca Gt Cca aac Gat A Cc TC CCG CTT CAC CAA
TACCGCGATCCAAGCTTATC
CTAGA Gt Cca aac Gat ACc TC CCG CTT CAC CAA gCT GCT cCT gcg cC
TACCGCGATCCAAGCTTATC
CTAGA GCc CTT CGtt CcC T ca TcC TGA AGA Aca Gt Cca aac Gat A Cc TCC CGC
CTAGA GC TCT TCG GGC TCT GG TGC TGA AGA ACC Gt Cca aac GAt ACc TCC CGC
CTAGA GC cCT TCG ttCcC T ca TcC TGA AGA Aca GG CCC TC GGA GAC TTC CCGCT
CTAGA GCT CTT CGG GCT CTG GTG aTG AAa AAC C GG CCC TCG GAG ACT
TACCGCGATCCAAGCTTATC
CTAGA GG CCCTCGGAGA CTTCCC atccgtc CAAACTG CTGCTCAAGC TAC
CTAGA GG CCCTCGGAGA CTTCCC accctgt CAAACTG CTGCTCAAGC TAC
CTAGA GCA CTAA GGG CTC T GG TGA TGA AAA ACC GGC CCT CGG AGA CTT CCC TCG
GAG ACT TCC Ctt TTt ACC AAA CTG CTG CTC AAGC
CTAGA GGA GCT CTT GGC CTT TAA AGT
CTAGA GAA GCT GCT GTC CTT CCG GGT
CTAGA TGC CAG ATC TTC GAT CTT TAA
CTAGA TGC CGG ACC TGC GGA CCC TGA
CTAGA TA CCG CGA TCC AAG CTT ATC
TTC GAT TCT GTA CAA GGG GGC AG
TTC GAT TCT GTA CAG TTA CCA TC
CCC TTA GTG CCG AAG AGC CCG
CTA GAG ACC TGC TCA ATG CC
GCA CTA AGG GCT CTG GTG ATG AAA AAC CGG CCC TCG GAG ACT TCC CTC GGA GAC
TTC CCT TTT TAC CAA ACT GCT GCC G
TTT TCA TCA CCA GAG CCC TTA GTG CCC GCA GCA GCG

69
792F
793F
794F
795R
796F
797R
798F
799R

adding T7 promoter for GR
adding T7 promoter for bGR
3'ss probe forward
T7 promoter for 3'ss probe
T7 promoter for alpha R70
Reverse for alpha R70
T7 promoter for beta R70
reverse for beta R70

F
F
F
R
F
R
F
R

CGA AAT TAA TAC GAC TCA CTA TAG GGA GAT ACA AGG GGG CAG CGG CAG A
CGA AAT TAA TAC GAC TCA CTA TAG GGA GAT ACA GTT ACC ATC AGT TCA T
CGA CCT CGA GGG CCC GGT ACC ATT CCA GAG GCT CAT CTT GGA AT
CGA AAT TAC GAC TCA CTA TAG GGA GAC CTC GTC AGA GGA AGA GGA G
CGA AAT TAA TAC GAC TCA CTA TAG GGA GAA GCT TGA GCA GCA GTT TG
GCT CTT CGG GCT CTG GTG CTG
CGA AAT TAA TAC GAC TCA CTA TAG GGA GAA CTT TAG AAG CAG TTT TGT A
GCA CTA AGG ACC TTA ATA ATG
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Primers for in vivo studies
Number
905R
936F
937R
1467R
1468R
1469F
1470F
1471F
1472F
1473F
1474F
1475R
1476F
1477R
1478F
1479R
1480F
1481R
1482R
1483F
1484R
1485F
1490F
1491R
1492F
1493R
900F
1494R
1495R
1496R

Description of plasmid construct
TRa2 146bp
TRa1 skip x9A 291bp
TRa1 skip x9A 291bp
rTRa2 135bp
rTRa2 140bp
rTRa2del5'ss 190bp
rTRa2 5'ss6TG192bp
TRa2 wt 5'ss 192bp
CSS1 51bp
CSS2 48bp
cross TRa3 185bp
cross TRa3 185bp
cross TRa3 127bp
cross TRa3 127bp
cross b200 css 129bp
cross b200 css 129bp
b200 insert139bp
b200 insert139bp
b200 insert189bp
TRa2 ZCSS-2 89bp
TRa2 ZCSS-2 89bp
TRa2 ZCSS-2 89bp
R100betaA
G100a B
R100a C
G100betaD
Exon 9A
Corrected R123 primer
TRa3 in wt or betaG100
TRa3 in betaR100

Direction
R
F
R
R
R
F
F
F
F
F
F
R
F
R
F
R
F
R
R
F
R
F
F
R
F
R
F
R
R
R

Sequence (5' to 3')
CCT CGT CAG AGG AAG AGG AG
CCT GGA TGA TAC GGA AGT GG
TCC TCA AAG ACC TCC AGG AA
TCG AAC TCT GCA CTT CTC TCT C
CAG AAT CGA ACT CTG CAG TTC T
TGC TGA TGA CCC ACA CAG AT
GCT GCT GAT GAA GGT GAC G
GCT GCT GAT GGT GAC TG
CGC TTC CTC CAC ATG AGA
GCG GCC AGA GGG AGA
ATA CGG AAG TGG CTC TGC TG
GAC CTG CGG ACC CTT CAT
GCT GTG TGT GGA CAA GAT CG
GAC CTG CGG ACC CCT CAT
GCT GTG TGT GGA CAA GAT CG
CGT GCA CTA AGG ACC TTC ATC
CAC AAC ATT CCG CAC TTC TG
TGA GGA GCT CTT GGC CTT TA
TCA CCC TTA AGG CCT TTG TT
TTC CTG GAG GTC TTT GAG GAT
CCC CCT TGT ACA GAA TCG AA
CCC ACT CTT CCT GGA GGT CT
CCG GCA ACT TTA GAA GCA GTT TTG TA
TAA AGT TGC CGG ACC TGC GGA CCC TG
CTG GCA GCT TGA GCA GCA GTT TGG TG
TCA AGC TGC CAG ATC TTC GAT CTT TA
TGT GTG TGG ACA AGA TCG AG
AAA CTG CTG CTC AAG CTG CC
TCA CCA AAC TGC TGC TCA A
TTT ACA AAA CTG CTT CTA AAG TTG C

71
1497R
1498R
1499aR
1499bR

betaR100 or GR200 css
betaR100 or GR200 css
TRa 9A w/936F 86bp
TRa 9A w/936F 137bp

R
R
R
R

TTG CAG GAA ACT CTC ATT CG
AGG CTT TGC AGG AAA CTC TC
CGA TCT TGT CCA CAC ACA GC
GGT GGT TGA CGT AGT GCT CA

Primers in realtime PCR analysis
Code
A
A1
A2

Number
936F
937R
1499bR

Description of plasmid construct
TRa1 skip x9A 291bp
TRa1 skip x9A 291bp
TRa 9A w/936F 137bp

Direction
F
R
R

Sequence (5' to 3')
CCT GGA TGA TAC GGA AGT GG
TCC TCA AAG ACC TCC AGG AA
GGT GGT TGA CGT AGT GCT CA

B
B1
B2
B3

900F
1467R
905R
1495R

Exon 9A
rTRa2 135bp
TRa2 146bp
TRa3 in wt or betaG100

F
R
R
R

TGT GTG TGG ACA AGA TCG AG
TCG AAC TCT GCA CTT CTC TCT C
CCT CGT CAG AGG AAG AGG AG
TCA CCA AAC TGC TGC TCA A

